Aptevo Therapeutics (NASDAQ:APVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, September 23rd.

Aptevo Therapeutics Stock Up 15.3 %

NASDAQ:APVO opened at $0.31 on Friday. The company has a 50 day simple moving average of $0.22 and a two-hundred day simple moving average of $0.42. Aptevo Therapeutics has a 12 month low of $0.14 and a 12 month high of $10.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.